Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Multicenter, Open and Phase II Clinical Study of HX008 for the Treatment in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03704246
• Other study ID #: HX008-II-02
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: September 30, 2018
• Est. completion date: March 30, 2021

Study information

• Verified date: March 2021
• Source: Taizhou Hanzhong biomedical co. LTD
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, patients of advanced gastric adenocarcinoma with failed first-line chemotherapy-line or advanced mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) advanced solid carcinoma will be treated with HX008 combined with irinotecan and HX008 monotherapy There will be two cohorts in this study: Cohort 1 and Cohort 2. For Cohort 1, advanced gastric adenocarcinoma with failed first-line chemotherapy-line cancer participants, who had failed or were unable to tolerate first line chemotherapy with platinum-based or fluorouracil regimens. For Cohort 2, advanced solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy.

Description:

Cohort 1: Currently, no PD-1 antibody against gastric cancer have been approved in China, and there are many patients with gastric cancer in China, so effective, low-toxicity and affordable treatment is urgently needed. This study aims to investigate the efficacy of combined application of recombinant human anti-PD-1 monoclonal antibody (HX008) and irinotecan in patients with locally advanced or metastatic gastric cancer (including gastric esophageal junction cancer) ,thus providing a better treatment for Chinese patients with gastric cancer.Advanced gastric adenocarcinoma with failed first-line chemotherapy-line cancer participants, who had failed or were unable to tolerate first line chemotherapy with platinum-based or fluorouracil regimens are needed. Cohort 2: Later-line therapies after failure of standard treatments for advanced solid cancer patients are limited. Mismatch repair (MMR) deficiency or microsatellite instability-high (MSI-H) played a role of positive predictive factor, which had been documented after the pembrolizumab and nivolumab trial were reported, for PD-1 blockade monotherapy in patients with advanced solid carcinomas. In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) advanced solid tumors will be treated with HX008 monotherapy.Advanced solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy are needed.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 123
• Est. completion date: March 30, 2021
• Est. primary completion date: December 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Main inclusion Criteria:

1. Subject is male or female; = 18 and = 75 years of age for cohort 1 and = 18 years of age for cohort 2 on the day of signing informed consent, and subject has voluntarily agreed to participate by giving written informed consent.

2. Subjects must have a histopathological diagnosis of any locally advanced or metastatic solid tumor, Subjects must have failed established standard medical anti-cancer therapies ( have disease progression after the therapies or be intolerant to the therapies) or Subjects refuse to standard therapies, or no effective treatment.

3. Subject must have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

4. Measurable disease as defined by RECIST v1.1.

5. Life expectancy = 12 weeks.

6. Subject must have adequate hematologic and organ function.

7. Asymptomatic patients with Central Nervous System (CNS) metastasis or asymptomatic brain metastasis after treatment shall undergo computed tomography (CT) or magnetic resonance imaging (MRI) for no disease progression, stable for at least 3 months and no steroid treatment for at least 4 weeks.

8. Male subjects and female subjects should agree to take effective contraception from the date of signing the informed consent form until 3 months after the last administration. Special inclusion criteria 1 in the Cohort 1.

1. Locally advanced or metastatic gastric adenocarcinoma (including gastric esophageal junction cancer) diagnosed histologically or cytologically.

2. Participants who had previously received a platinum-based or fluorouracil based first-line chemotherapy failed or could not tolerate.

3. The final cytotoxic drug, radiotherapy, or surgery=4 weeks away. Special inclusion criteria 1 in the Cohort 2 1.Advanced malignant solid tumors confirmed by histology or cytology and confirmed as msi-h or dMMR by the central laboratory designated by the sponsor. 2.Participants must have received or not tolerated a first-line anti-tumor drug regimen.

Main exclusion Criteria:

1. Participants with other malignant tumors within 5 years before enrollment, excluding cured cervical carcinoma in situ and cured basal cell carcinoma of the skin.

2. Subject Is currently participating and receiving study therapy or has participated in a study of an investigational agent and receive study therapy within 28 days of the first dose of study drug.

3. Subject has not recovered to CTCAE Grade 1 or better from the adverse events due to cancer therapeutics administered.

4. Subject who had received anti-PD-1, PD-L1-,CTLA-4 monoclonal therapy, etc.

5. Subjects with active, or pre-existing, autoimmune diseases that may recur.

6. Systemic corticosteroids should be administered within 14 days before initial administration or during the study.

7. Subjects with active gastrointestinal ulcer, incomplete intestinal obstruction, active gastrointestinal hemorrhage and perforation.

8. Subjects with existing interstitial lung or pneumonia, pulmonary fibrosis, acute pulmonary disease, radioactive pneumonia;

9. Subjects with Uncontrollable and stable systemic diseases, such as cardiovascular and cerebrovascular diseases, diabetes, hypertension and tuberculosis.

10. Subjects with a history of infection with human immunodeficiency virus, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation or stem cell transplantation.

11. Subject is positive for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active hepatitis B (HBV surface antigen positive and HBV DNA = 500 copies/ml)or hepatitis C or tuberculosis (HCV antibody positive).

12. Subjects with severe infection within 4 weeks before first administration, or those with active infection within 2 weeks before administration or intravenous antibiotic treatment.

13. Subjects who have been previously known to have severe allergic reactions to macromolecules/monoclonal antibodies or to any of the test drug components (CTCAE =Grade 3).

14. Participated in clinical trials of other drugs within 4 weeks before the first administration (subject to the use of the tested drugs).

15. Subjects with alcohol dependence or a history of drug abuse or drug abuse within one year.

16. Subjects with a clear history of neurological or mental disorders, such as epilepsy, dementia, poor compliance, or peripheral nervous system disorders;

17. Subjects with symptomatic brain metastases.

18. Women who are pregnant or lactating.

19. Subjects were not fit for other reasons concluded by the researchers.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• Anti-PD-1 monoclonal antibody
HX008 is a monoclonal antibody drug which is intravenous drip at a dose of 200mg.

Locations

Country	Name	City	State
China	Affiliated Hospital of Hebei University	Baoding
China	Beijing Yuhe Combination of Chinese Traditional and Western Medicine Recovery Hospital	Beijing
China	Cancer Hospital, Chinese Academy of Medical Sciences	Beijing	Beijing
China	The First Affiliated Hospital of Bengbu Medical College	Bengbu
China	Hunan Cancer Hospital	Changsha
China	Xiangya Hospital, Central South University	Changsha
China	Heping Hospital Affiliated to Changzhi Medical College	Changzhi
China	Fujian Cancer Hospital	Fuzhou
China	The First Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou
China	Zhejiang Cancer Hospital	Hangzhou
China	The affiliated Cancer Hospital of Harbin Medical University	Harbin
China	Anhui Provincial Cancer Hospital	Hefei
China	Shandong Cancer Hospital	Jinan
China	Jiangsu Provincial People's Hospital	Nanjing
China	Guangxi Medical University Cancer Hospital	Nanning
China	Fudan University Cancer Center	Shanghai
China	Liaoning Cancer Hospital	Shenyang
China	The First Hospital of China Medical University	Shenyang
China	Peking university shenzhen hospital	Shenzhen
China	The Fourth Hospital of Hebei Medical University	Shijiazhuang
China	The Second Affiliated Hospital of Soochow University	Suzhou
China	Shanxi Cancer Hospital	Taiyuan
China	Tianjin Cancer Hospital	Tianjin
China	Tianjin People's Hospital	Tianjin
China	Hubei Cancer Hospital	Wuhan
China	Wuhan Central Hospital	Wuhan
China	The First Affiliated Hospital of Xi'an Jiaotong University	Xian
China	The First Affiliated Hospital of Xinxiang Medical College	Xinxiang
China	Henan Cancer Hospital	Zhengzhou
China	The First Affiliated Hospital of Zhengzhou University	Zhengzhou

Sponsors (1)

Lead Sponsor	Collaborator
Taizhou Hanzhong biomedical co. LTD

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR of HX008 combined with irinotecan and HX008 single drug	ORR was assessed according to Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST 1.1)	Up to approximately 2 years
Secondary	HX008 safety and tolerability assessed by monitoring AEs	Percentage of participants with adverse events (AEs), serious adverse events and AEs of special interest	From screening to up to 1 months after the last dose of study drug (up to approximately 2 years)
Secondary	Disease Control Rate (DCR)	per RECIST 1.1 assessed by central imaging vendor and investigator	Up to approximately 2 years
Secondary	Duration of Response (DOR)	per RECIST 1.1 assessed by central imaging vendor and investigator	Up to approximately 2 years
Secondary	Progression-Free Survival (PFS)	per RECIST 1.1 assessed by central imaging vedor and investigator	Up to approximately 2 years
Secondary	Overall Survival (OS)	Calculated by the Kaplan-Meier method.	Up to approximately 2 years
Secondary	Immunogenicity	Measured by MSD electroluminescence detection method	From the first dose of study drug (up to approximately 2 years)